Cell Targeting, Inc., 11000 Cedar Ave., Cleveland, OH 44106, USA.
Curr Opin Biotechnol. 2009 Oct;20(5):531-6. doi: 10.1016/j.copbio.2009.08.009. Epub 2009 Sep 23.
Mesenchymal stem cell (MSC)-based therapeutics are showing significant benefit in multiple clinical trials conducted by both academic and commercial organizations, but obstacles remain for their large-scale commercial implementation. Recent studies have attempted to optimize MSC-based therapeutics by either enhancing their potency or increasing their delivery to target tissues. Overexpression of trophic factors or in vitro exposure to potency-enhancing factors are two approaches that are demonstrating success in preclinical animal models. Delivery enhancement strategies involving tissue-specific cytokine pathways or binding sites are also showing promise. Each of these strategies has its own set of distinct advantages and disadvantages when viewed with a mindset of ultimate commercialization and clinical utility.
基于间充质干细胞（MSC）的疗法在学术和商业组织进行的多项临床试验中显示出显著的益处，但在大规模商业化实施方面仍存在障碍。最近的研究试图通过增强其效力或增加其向靶组织的输送来优化基于 MSC 的疗法。生长因子的过表达或体外暴露于增强效力的因子是两种在临床前动物模型中取得成功的方法。涉及组织特异性细胞因子途径或结合位点的输送增强策略也显示出前景。当从最终商业化和临床实用性的角度来看，每种策略都有其独特的优点和缺点。
